KMT2A and acute myeloid leukemia: More detailed dose-response analysis was performed with CCI-007 on an expanded panel of leukemia cell lines composed of eleven MLL-r (8 ALL, 3 AML) and eight MLL-wt (4 ALL, 4 AML) leukemia cell lines.